Sionna Therapeutics (NASDAQ:SION) Trading Down 14.6% Following Insider Selling

Sionna Therapeutics, Inc. (NASDAQ:SION) shares were down 14.6% on Thursday after an insider sold shares in the company. The stock traded as low as $34.30 and last traded at $35.27. Approximately 269,413 shares were traded during mid-day trading, a decline of 11% from the average daily volume of 304,275 shares. The stock had previously closed at $41.31.

Specifically, Director Peter A. Thompson sold 29,063 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $44.58, for a total transaction of $1,295,628.54. Following the transaction, the director owned 3,530,702 shares of the company’s stock, valued at $157,398,695.16. This trade represents a 0.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Peter A. Thompson sold 1,890 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $44.57, for a total value of $84,237.30. Following the sale, the director directly owned 3,559,765 shares of the company’s stock, valued at approximately $158,658,726.05. This represents a 0.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 29,063 shares of Sionna Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $44.58, for a total value of $1,295,628.54. Following the transaction, the director directly owned 3,530,702 shares in the company, valued at approximately $157,398,695.16. This trade represents a 0.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Raymond James Financial reissued a “strong-buy” rating and issued a $53.00 price objective on shares of Sionna Therapeutics in a research note on Monday, January 5th. Royal Bank Of Canada restated an “underperform” rating and issued a $24.00 target price on shares of Sionna Therapeutics in a research note on Monday, December 1st. Lifesci Capital began coverage on shares of Sionna Therapeutics in a report on Tuesday, December 23rd. They issued an “outperform” rating and a $60.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Sionna Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $45.43.

Sionna Therapeutics Price Performance

The stock has a market cap of $1.61 billion and a price-to-earnings ratio of -7.41. The company’s 50 day moving average is $41.08 and its 200 day moving average is $32.95.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Institutional Investors Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Viking Global Investors LP raised its holdings in Sionna Therapeutics by 8.2% during the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after purchasing an additional 242,427 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Sionna Therapeutics by 2.4% in the second quarter. JPMorgan Chase & Co. now owns 2,221,188 shares of the company’s stock valued at $38,538,000 after purchasing an additional 51,589 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Sionna Therapeutics by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after buying an additional 41,797 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Sionna Therapeutics by 11.8% during the 4th quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock worth $45,883,000 after buying an additional 117,903 shares during the last quarter. Finally, Braidwell LP purchased a new stake in shares of Sionna Therapeutics in the 2nd quarter worth about $18,770,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.